{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:19:37Z","timestamp":1792120777438,"version":"4.4.0"},"reference-count":61,"publisher":"American Society for Clinical Investigation","issue":"9","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":44,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030715","name":"Hillman Cancer Center, Medical Center, University of Pittsburgh","doi-asserted-by":"crossref","award":["Cancer Immunology"],"award-info":[{"award-number":["Cancer Immunology"]}],"id":[{"id":"10.13039\/100030715","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100030715","name":"Hillman Cancer Center, Medical Center, University of Pittsburgh","doi-asserted-by":"crossref","award":["Immunotherapy Program (CIIP) Pilot Award"],"award-info":[{"award-number":["Immunotherapy Program (CIIP) Pilot Award"]}],"id":[{"id":"10.13039\/100030715","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cure within Reach","award":["Repurposing Research Grant in Hematologic Malignancies"],"award-info":[{"award-number":["Repurposing Research Grant in Hematologic Malignancies"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>The graft-versus-leukemia (GVL) effect contributes to the efficacy of allogeneic stem cell transplantation (alloSCT). However, relapse, indicative of GVL failure, is the greatest single cause of treatment failure. Based on preclinical data showing that IFN-\u03b3 is important to sensitize myeloblasts to alloreactive T cells, we performed a phase I trial of IFN-\u03b3 combined with donor leukocyte infusions (DLIs) in myeloblastic malignancies that relapsed after HLA-matched alloSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Patients with relapsed acute myeloid leukemia or myelodysplastic syndrome after alloSCT were eligible. Patients self-administered IFN-\u03b3 for 4 weeks (cohort 1) or 1 week (cohort 2), followed by DLI and concurrent IFN-\u03b3 for a total of 12 weeks. Bone marrow samples were analyzed by single-cell RNA sequencing (scRNA-Seq) to assess in vivo responses to IFN-\u03b3 by malignant myeloblasts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      IFN-\u03b3 monotherapy was well tolerated by all participants (\n                      <jats:italic>n<\/jats:italic>\n                      = 7). Treatment-related toxicities after DLI included grade I\u2013II graft-versus-host disease (\n                      <jats:italic>n<\/jats:italic>\n                      = 5), immune effector cell\u2013associated neurotoxicity syndrome (\n                      <jats:italic>n<\/jats:italic>\n                      = 2), and idiopathic pulmonary syndrome (\n                      <jats:italic>n<\/jats:italic>\n                      = 1), all of which resolved with corticosteroids. Four of 6 DLI recipients achieved minimal residual disease-negative complete remissions and full donor hematopoietic recovery. Median overall survival was 579 days (range, 97\u2013906) in responders. scRNA-Seq validated in vivo activation of the IFN-\u03b3 response pathway in hematopoietic stem cell\u2013like or myeloid progenitor cells after IFN-\u03b3 in analyzed samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>IFN-\u03b3 was safe and well tolerated in this phase I study of IFN-\u03b3 for relapsed acute myeloid leukemia and myelodysplastic syndrome after alloSCT, with a promising efficacy signal when combined with DLI. Larger studies are needed to formally test the efficacy of this approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT04628338.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>FUNDING<\/jats:title>\n                    <jats:p>UPMC Hillman Cancer Center Cancer Immunology and Immunotherapy Program Pilot Award and Cure Within Reach: Drug Repurposing Clinical Trials to Impact Blood Cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1172\/jci.insight.190655","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T14:00:36Z","timestamp":1746626436000},"source":"Crossref","is-referenced-by-count":5,"title":["IFN-\u03b3 and donor leukocyte infusions for relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1172","volume":"10","author":[{"given":"Sawa","family":"Ito","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine;"},{"name":"Thomas E. Starzl Transplantation Institute; and"},{"name":"Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Geramita","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kedwin","family":"Ventura","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswas","family":"Neupane","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Bhise","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington School of Medicine, Fred Hutchinson Cancer Center, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika M.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-9840","authenticated-orcid":true,"given":"Scott","family":"Furlan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington School of Medicine, Fred Hutchinson Cancer Center, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren D.","family":"Shlomchik","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine;"},{"name":"Thomas E. Starzl Transplantation Institute; and"},{"name":"Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1365"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.05.005"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.02.025"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.08.016"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0171-z"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2091"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375840"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082255"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1605066"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.07.005"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3185-5"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.004"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.016"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.10"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.7"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26540"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00437-z"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04398-y"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04321-x"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188094"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01416-5"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.05.011"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04674-x"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.433"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.3.555.555"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199401133300204"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6053"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02293"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3735"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-125294"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85736"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-304121"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386995"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac099"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005509"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009376"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808777"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0400-z"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17991-y"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019875"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91138"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402157"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39165"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.3.1272"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400954"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402865"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.06.028"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad1021"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024105"},{"key":"B52","unstructured":"Tickle T, et al. inferCNV of the Trinity CTAT Project. https:\/\/github.com\/broadinstitute\/infercnv\/blob\/master\/inst\/CITATION#L1. Updated 2019. Accessed March 24, 2025"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111697"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2015.12.004"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae909"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3192"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-151504"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-020-0820-1"},{"key":"B61","unstructured":"inferCNV of the Trinity CTAT Project. https:\/\/github.com\/broadinstitute\/inferCNV Accessed March 24, 2025"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/190655\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:42:56Z","timestamp":1779126176000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/190655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,4,8]]},"published-print":{"date-parts":[[2025,5,8]]}},"alternative-id":["10.1172\/jci.insight.190655"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.190655","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"article-number":"e190655"}}